SyndicateNL brings together plant-derived material, consumer skincare reference and professional product-development dialogue. We keep each route distinct so that material, category and market questions can be discussed with appropriate context.
Natural science / European context
Our frame
We start with the material and the intended use, then keep consumer, professional and research pathways distinct.
Company introduction
A European-oriented material company.
SyndicateNL is an industrial-hemp and cannabidiol technology company with a European focus. Its public work is organised across CBD Skincare for consumer reference, CBD API and cosmetics dialogue for professional teams, and early medical-device research concepts. Each area is presented according to its own intended use, evidence context and market discussion.
Three distinct pathways
01 / CONSUMER REFERENCE
CBD Skincare
Consumer-facing skincare and personal-care context, with current product details communicated through live store listings and applicable market information.
02 / PROFESSIONAL DIALOGUE
CBD API & Cosmetics
Project-led discussion for material, formulation and category questions. Scope, documentation and intended market are reviewed case by case.
03 / RESEARCH CONTEXT
Medical Device Concepts
Research concepts are presented according to their declared stage, without inferring approval, availability or clinical outcome.
Team introduction
A team organised by the question.
Meet the people behind the material, product and research conversations. Their individual public profiles are verified from the SyndicateNL team video and presented in a dedicated team directory.
01
Material & formulation
Professional dialogue for material scope, formulation questions and the documentation context required for a specific project.
02
Product & category
Category-focused discussion for consumer skincare reference and intended-market context, led by the relevant product pathway.
03
Research & documentation
Stage-aware research dialogue for declared preclinical concepts, with no implication of approval, clearance or commercial availability.